why choose us

First received: June 16, 2023

Clinical Trial: Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Gastric Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Ta

Brief Summary: This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

Read more